Unknown

Dataset Information

0

Design, synthesis, and structure activity relationship analysis of new betulinic acid derivatives as potent HIV inhibitors.


ABSTRACT: Prior modification of betulinic acid (1), a natural product lead with promising anti-HIV activity, produced 3-O-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat, 3), the first-in-class HIV maturation inhibitor. After 3-resistant variants were found during Phase I and IIa clinical trials, further modification of 3 produced 4 with improved activity against wild-type and 3-resistant HIV-1. In continued efforts to optimize 1, 63 final products have now been designed, synthesized, and evaluated for anti-HIV-1 replication activity against HIV-1NL4-3 infected MT-4 cell lines. Five known and 21 new derivatives were as or more potent than 3 (EC50 0.065 μM), while eight new derivatives were as or more potent than 4 (EC50 0.019 μM). These derivatives feature expanded structural diversity and chemical space that may improve the antiviral activity and address the growing resistance crisis. Structure-Activity Relationship (SAR) correlations were thoroughly analyzed, and a 3D Quantitative SAR model with high predictability was constructed to facilitate further rational design and development of new potent derivatives.

SUBMITTER: Zhao Y 

PROVIDER: S-EPMC8176629 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Design, synthesis, and structure activity relationship analysis of new betulinic acid derivatives as potent HIV inhibitors.

Zhao Yu Y   Chen Chin-Ho CH   Morris-Natschke Susan L SL   Lee Kuo-Hsiung KH  

European journal of medicinal chemistry 20210214


Prior modification of betulinic acid (1), a natural product lead with promising anti-HIV activity, produced 3-O-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat, 3), the first-in-class HIV maturation inhibitor. After 3-resistant variants were found during Phase I and IIa clinical trials, further modification of 3 produced 4 with improved activity against wild-type and 3-resistant HIV-1. In continued efforts to optimize 1, 63 final products have now been designed, synthesized, and evaluated for  ...[more]

Similar Datasets

| S-EPMC2860721 | biostudies-literature
| S-EPMC3426442 | biostudies-literature
| S-EPMC3541990 | biostudies-literature
| S-EPMC7442216 | biostudies-literature
| S-EPMC8746797 | biostudies-literature
| S-EPMC10093915 | biostudies-literature
| S-EPMC2788670 | biostudies-literature
| S-EPMC2736638 | biostudies-literature
| S-EPMC7070564 | biostudies-literature
| S-EPMC2656571 | biostudies-literature